As oncology practices strive to deliver high-quality, cost-conscious care to patients, alternative payment models such as the CMS Innovation Center’s Enhancing Oncology Model (EOM) and models from commercial payers have been explored as avenues to encourage quality care.
Kathy Oubre, MS | Image credit: LinkedIn
Although adopting new payment models can come with challenges, there are strategies that can help practices optimize their approaches, Kathy Oubre, MS, said in an interview with Evidence-Based Oncology (EBO). Oubre is CEO of Pontchartrain Cancer Center in Covington, Louisiana.
This interview is lightly edited for clarity.
EBO: What are some of the biggest challenges oncology practices face when adopting new payment models?
Oubre: I think the biggest challenge that practices face when bringing on a new payment model is getting everyone in the organization on board with that new model to understand the “why” and to understand the workflows and the value to the practice as well as the patients.
EBO: How are practices addressing the infrastructure and resource challenges associated with these new payment models?
Oubre: There are a lot of new strategies and innovations available in the cancer care space when thinking about value-based care. Practices need to think judiciously about that because there are small solutions for every facet of value-based care. But that’s a lot of technology to keep up with. We need to spend time figuring out what we can handle on a practice level with our resources and where we need to make partnerships so those facets of the value-based care model work better.
Some of the resource challenges [include] the finances behind all the different technologies that practices can take advantage of to help in value-based care. All of those things have a cost, which then eats into the overall cost, or margin, of a practice. So you have to be judicious in how you bring those things online. But there are some really good models out there.
For example, there’s some [well-designed] software that helps practices. We’ve been doing principal care management for the past year. We’ve been doing that within the EMR [electronic medical records], but it’s more of a paper process, or lack of an automated process. So we brought on a software vendor to help us automate it and make it more seamless within the organization. And we saw a tremendous uptake in our patients. We saw pretty good adoption as to the “why” and the understanding in our employees. And within probably a month of utilizing that vendor, we were able to turn that investment into a profit, which helps us, helps the patient, and helps the payer.
EBO: In your opinion, what roles do policy development and regulatory support play in ensuring the continued success and sustainability of alternative payment models?
Oubre: When we’re considering payment policies and regulatory issues around patients and patient care, we need to remember that 1 size does not fit all when we’re designing these models. We see that when looking at social determinants of health. We treat a wide variety of patients—we treat individuals with master’s degrees and those who have an eighth-grade education, those who are in the top 1% and those who need food bank assistance. So when we’re designing these models and how we think
things should work, be that OCM [Oncology Care Model] or EOM [Enhancing Oncology Model] or a commercial payer model, we need
to consider that there’s a large variability of patients we have to serve to fulfill our mission as a practice.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Managed Care Reflections: A Q&A With John Michael O’Brien, PharmD, MPH
May 5th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The May issue features a conversation with John Michael O’Brien, PharmD, MPH, a member of AJMC’s editorial board and the president and CEO of the National Pharmaceutical Council. This interview has been lightly edited for clarity.
Read More
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More